spacer
home > ict > winter 2009 > the latin beat
PUBLICATIONS
International Clinical Trials

The Latin Beat

 

The experience of running clinical trials in Latin America has improved markedly in recent years in line with the breadth of resources and expertise now available in the region. Graciela Rácaro at PAREXEL International examines the pace of evolution during the last decade

Latin America has evolved as an important area for clinical research, and the industry has shown increasing interest in the emerging region that will serve as a potential new end market for biopharmaceutical products. While clinical trial sponsors used to consider Latin America primarily in large studies or for clinical trials that could not achieve the required patient recruitment on time in ‘traditional’ research countries, more recently they have included the region from the beginning when planning their product development programmes.

Latin America has evolved as an important area for clinical research, and the industry has shown increasing interest in the emerging region that will serve as a potential new end market for biopharmaceutical products. While clinical trial sponsors used to consider Latin America primarily in large studies or for clinical trials that could not achieve the required patient recruitment on time in ‘traditional’ research countries, more recently they have included the region from the beginning when planning their product development programmes.

The growth of clinical trials in Latin America (which is linked to FDA/EMEA acceptance of foreign research data, a huge pool of potential trial patients, and the globalisation of clinical research) should be assessed not only in terms of the number of studies conducted in the region, but also through the experience gained during the last few years.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Graciela Rácaro is Senior Director, Clinical Operations, Latin America at PAREXEL International. She is responsible for all clinical and regulatory activities in Latin America. Graciela specialises in drug development and non-clinical and clinical research. Her background includes serving as clinical lead and project manager for Latin American projects as well as global programmes. Prior to joining PAREXEL, Graciela held a clinical management position at Serono International, and previously worked at the clinical research organisation EDYABE and pharmaceutical company Laboratorio Gador, SA. Graciela holds BCh and Pharm degrees from the College of Pharmacy and Biochemistry at the University of Buenos Aires, and completed her Masters in Clinical Research and Clinical Trials Monitoring at the University Maimónides College of Medicine in Buenos Aires. Email: graciela.racaro@parexel.com

 

spacer
Graciela Rácaro
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

SCOPE Europe – Summit for Clinical Ops Executives Europe

17-18 September 2019, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical innovation leaders, clin ops execs, functional heads, category managers, and those responsible for the planning and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, five conference tracks, interactive breakout discussion groups, and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement